Organizations that continue to anchor development programs in broad diagnostic categories and legacy clinical endpoints face a structural disadvantage. The issue is not weak science, but outdated development frameworks. Salience Clinical operates at the intersection of neuroscience, regulatory strategy, and precision development helping sponsors translate biological insight into approvable therapies, differentiated labels, and sustainable market positioning.